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Abstract
Background: End-Stage Renal disease (ESRD) is associated with increased morbidity and mortality. We assessed the
occurrence, time-trend and determinants of fatal outcomes of haemodialysis-treated ESRD patients over a 10-year
period in a major referral hospital in Cameroon.
Methods: Medical records of ESRD patients who started chronic haemodialysis at the Douala General Hospital
between 2002 and 2012 were reviewed. Baseline characteristics and fatal outcomes on dialysis were recorded.
Accelerated-failure time and logistic regression models were used to investigate the determinants of death.
Results: A total of 661 patients with 436 (66 %) being men were included in the study. Mean age at dialysis
initiation was 46.3 ± 14.7 years. The median [25th–75th percentiles] duration on dialysis was 187 [34–754] days.
A total of 297 (44.9 %) deaths were recorded during follow-up with statistical difference over the years (p < 0.0001
for year by year variation) but not in a linear fashion (p = 0.508 for linear trend), similarly in men and women
(p = 0.212 for gender*year interaction). The death rate at 12 months of follow-up was 26.8 % (n = 177), with
again similar variations across years (p < 0.0001). In all, 34 % of deaths occurred within the first 120 days.
Year of study and background nephropathies were the main determinants of mortality, with the combination
of diabetes and hypertension conveying a 127 % (95 % CI: 40–267 %) higher risk of mortality, relative to
hypertension alone.
Conclusion: Mortality in dialysis is excessively high in this setting. Because most of these premature deaths
are potentially preventable, additional efforts are needed to offset the risk and maximise the benefits from
the ongoing investments of the government to defray the cost of haemodialysis. Potential actions include
sensitisation of the population and healthcare practitioners, early detection and referral of individuals with
CKD; and additional subsidies to support the cost of managing co-morbidities in patients with CKD in
general.
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Background
Chronic kidney disease (CKD) is a major public health
problem and was ranked as the 18th cause of death
worldwide in 2010, with most of these deaths occurring
in patients with End-Stage Renal Disease (ESRD) [1, 2].
It has been projected that by 2030 more than 70 % of
patients with ESRD will originate from low- and middle
income countries, such as those in sub-Saharan Africa
[3]. ESRD requiring renal replacement therapy (RRT) is
the common final pathway for CKD. The population of
patients on RRT has doubled in the last two decades.
Globally, the number of patients receiving RRT was
estimated to be over 1.8 million in 2004, with less
than 5 % of this population residing in sub-Saharan
Africa (SSA) [4].
Maintenance dialysis therapy is the commonest mode
of RRT and demand for this service is increasing with
the ESRD population. Although dialysis prevents death
from uraemia, patients’ survival remains an important
issue. Patients on dialysis have a 3–8 times higher mor-
tality rate than the general population, essentially from
increased cardiovascular morbidities [5–7]. There are
suggestions that major developments in the management
of ESRD patients worldwide have not benefited patients
in low- and middle income countries where access to
RRT and outcomes of care remain very poor [8–10]. As
a result, the mortality rate within 90 days of commen-
cing RRT in SSA countries is as high as 90 %, compared
with European countries where it is about 3 % [10, 11].
However existing data from African countries is very
patchy and do not reflect the contemporary profile of
ESRD patients and patterns of care in this setting.
Dialysis was introduced in Cameroon in the early
1980s and included both peritoneal and haemodialysis,
although for over 20 years now haemodialysis has been
the only modality of RRT available in the country [12].
For many years however, access to dialysis services in
the country has been restricted to few centres (at most
three) in the two main cities of the country (Yaoundé
and Douala). It is only within the last eight years that
the government has expanded haemodialysis services in
terms of geographic coverage and capacity to cope with
increasing demand. Nevertheless, data regarding the out-
come of patients on RRT in Cameroon is inexistent, a
situation which is shared by most countries in SSA. The
aim of this study was to report on the occurrence, time-
trend and determinants of major outcomes of
haemodialysis-treated ESRD over a 10 years period in a
referral tertiary hospital in Cameroon.
Methods
Study setting and clinical pathway of patients with ESRD
This prospective study was carried out in the renal
unit of the Douala general hospital (DGH) in
Cameroon, and covered the period from 2002 to
2012. DGH is a 320 bedded public institution, which
serves as referral hospital for kidney diseases for the
Littoral region of the country (approximately 3 mil-
lion population in 2012) and beyond. The haemodi-
alysis unit of DGH including the staff, equipment and
pathway of patients with ERSD, has been described in
details previously [13]. At the end of the year 2012, the
unit was operating with one nephrologist, two general
practitioners and 12 nurses and was equipped with 17
hemodialysis Fresenius® 4008S generators (Fresenius
Medical Care, Hamburg, Germany), synthetic polysulfone
dialysis membrane, and bicarbonate dialysate was used.
Patients in this unit received two weekly sessions of 4 h
haemodialysis. Each patient with ESRD has at initiation of
dialysis a clinical assessment and laboratory investigations.
The register of patients with ESRD starting RRT in the
DGH served as basis for patients’ recruitment. This study
received administrative authorization from the DGH and
was approved by the ethic committee of the Douala
University, Cameroon.
The total population in Cameroon was estimated to
be about 21.7 million in 2012, with 16.5 % aged less
than five years. The total health expenditure was
equivalent to 4.3 % of the gross domestic product
(GDP), and the general government health expendi-
tures represented about 24.6 % of the total health ex-
penditure and 5.5 % of the general government
expenditure [14]. Therefore, in the absence of social
security system in Cameroon, out-of-pocket spending
represent an important proportion of the health ex-
penditure. However, access to haemodialysis in public
health facilities is highly subsidized by the govern-
ment since 2002, with the co-contribution of patients
representing about 5 % of dialysis session cost [13].
In 2012, the country had a total of five nephrologists
(two in Douala), eight haemodialysis centres with two
in Douala including the study centre and a private
haemodialysis centre. The eight centres were provid-
ing care to about 500 patients on chronic dialysis,
with 30 % (140) of them being managed at the study
centre [13].
Data collection
This study included a total of 661 patients with ESRD
on regular haemodialysis at the DGH in Cameroon and
was done in the period from the 1st January to 30 June
2013. The case records of all patients with ESRD on
RRT over a 10-year period (2002–2012) were retrieved.
Data were extracted for each patient on age, sex, major
comorbidities (hypertension, diabetes, HIV, gout, history
of stroke), the presumed aetiology of ESRD, key parame-
ters at dialysis initiation and the vital status at the last
contact with the service.
Halle et al. BMC Nephrology  (2016) 17:165 Page 2 of 9
Operational definitions
The diagnosis of ESRD was based on the following:
estimated glomerular filtration rate using the Cock-
croft and Gault formula (from 2002 to 2010) or the
four-variable Modification of Diet in Renal Disease
(MDRD) formula (from 2010 and beyond) [15, 16]
(eGFR) less than 15 ml/min/1.73 m2, bilateral
shrunken kidneys on ultrasound and presence CKD
risk factors and any clinical or biological signs of
uraemia. Hypertension, diabetes and HIV were based
on documented history, ongoing drug treatments or a
documented systolic blood pressure (BP) >140 mmHg
and/or diastolic BP >90 mmHg for hypertension or
fasting blood glucose >126 mg/dl, or a positive test
for HIV.
The background nephropathy was based on clinical
arguments in the absence of renal histology data.
Chronic glomerulonephritis was based either on a
documented history of glomerular disease or the pres-
ence of a glomerular syndrome (proteinuria and/or
haematuria, hypertension in the absence of identifi-
able secondary causes). Background nephropathy was
ascribed to HIV in the presence of a glomerular syn-
drome in an HIV positive patient with hyperecho-
genic and normal size kidneys on ultrasound. Diabetic
nephropathy was defined by the presence of hyperten-
sion in a diabetic patient associated with glomerular
proteinuria, diabetic retinopathy and normal size kid-
ney on ultrasound in the absence of any other cause.
CKD was attributed to hypertension in patients with
longstanding history of hypertension, and normal
urine sediment in the presence of other target organ
damages such as left heart hypertrophy, hypertensive
retinopathy, and bilateral shrunken kidneys. The aeti-
ology was mixed (diabetes and hypertension) in case
of longstanding history of diabetes and hypertension
in a patient with clinical sign of both nephropathy.
The Charlson comorbidity score was estimated by
adding up the scores assigned to existing comorbidi-
ties based on the risk of death associated with each
of them. The following comorbidities were considered:
congestive heart failure, coronary disease, diabetes
mellitus, malignancies, stroke, peripheral vascular dis-
ease, chronic obstructive pulmonary disease, HIV/
AIDS, chronic liver disease and connective tissue dis-
ease [17].
Unplanned dialysis was defined as dialysis initiation
without preparation, indicated for a life threatening situ-
ations using a temporary vascular access (non-tunnelled
polyureththane double lumen central venous catheter).
Patient’s outcome in this study refers to their status at
the last dialysis session – dead or alive. Deaths in the
first 120 days of initiation of dialysis were considered as
early mortality.
Statistical analysis
Data were analyzed with the use of SAS/STAT® v 9.1 for
Windows (SAS Institute Inc., Cary, NC, USA). We have
presented the results as count and percentages, mean
and standard deviation (SD) or median and 25th–75th
percentiles. Differences between men and women and
across years of study were investigated via chi square
tests and equivalents for qualitative variables, and linear-
ity in the trend across years assessed with the Cochran-
Armitage trend test, while the analysis of the variance
(ANOVA) and equivalents were used for quantitative
variables. The Kaplan-Meier estimator and accelerated
failure time models, implemented with the use of LIFET-
EST and LIFEREG procedures of SAS were used to in-
vestigate the baseline characteristics associated with
mortality during follow-up. Basic regression models were
adjusted for age, sex and year of study, while the ex-
tended multivariable models also comprised significant
predictors in basic models, based on a threshold for sig-
nificance of p ≤ 0.10. To test the robustness of our find-
ings, determinants were also investigated via logistic
regression models, both accounting for the entire dur-
ation of follow-up and after restriction of the outcomes
to those recorded within the first 12 months of starting
the dialysis. To maximize the stability of the estimates
across years of study, participants were grouped by clus-
ters of two consecutive years of observations. A p-value
<0.05 was used to characterize statistically significant
results.
Results
Sex and age distribution on dialysis overall and by year
of study
A total of 661 patients, with 436 (66 %) being men,
started RRT during the study period. The proportion of
men ranged from 69.2 % in 2002–2004 to 63.6 % in
2011–2012, with a nadir at 61.5 % in 2009–2010, and no
significant difference (p = 0.575), nor a linear trend (p =
0.187 for linearity) across years of study. The mean age
was 46.3 (SD = 14.7) years overall and ranged from 46.9
(15.7) years in 2002–2004 to 46.1 (14.5) years in 2011–
2012 again with no significant difference, nor a linear
trend across years of the study (both p ≥ 0.133), and
similarly among men and women (p = 0.840 for gender*-
year interaction).
Profile for chronic kidney disease overall and across years
of study
The distribution of the background nephropathy is de-
scribed in Table 1. Major identified etiologies were
hypertension (28.3 %), chronic glomerulonephritis
(17.5 %), diabetes mellitus (13.9 %), hypertension and
diabetes (7.3 %), HIV (6.7 %), other aetiologies (9.4 %);
while no aetiology was identified in 16.9 % of the
Halle et al. BMC Nephrology  (2016) 17:165 Page 3 of 9
Table 1 Profile of patients on dialysis and case-fatality overall and across years of the study
Variables Overall 2002–2004 2005–06 2007–08 2009–10 2011–12 p-value1 p-trend2 p year*
gender3
N (%) 661 (100) 120 (18.1) 153 (23.1) 111 (16.8) 156 (23.6) 121 (18.3)
Men, n (%) 436 (66.0) 83 (69.2) 103 (67.3) 77 (69.4) 96 (61.5) 77 (63.6) 0.575 0.187 NA
Mean age, years (SD) 46.3 (14.7) 46.9 (15.7) 48.3 (13.5) 44.9 (16.4) 45.2 (14.0) 46.1 (14.5) 0.282 0.133 0.840
Mean haemoglobin, g/dl (SD) 7.7 (2.0) 7.4 (2.3) 7.6 (1.9) 7.9 (1.8) 7.5 (1.9) 7.9 (1.9) 0.240 0.521 0.649
Mean Urea, g/l (SD) 2.60 (1.16) 2.28 (0.96) 2.48 (1.17) 2.67 (1.20) 2.74 (1.91) 2.8 (1.1) 0.009 0.003 0.661
Mean creatinine, mg/l (SD) 184.3 (88.9) 168.5 (87.5) 191.7 (104.8) 188.9 (87.3) 184.2 (82.2) 185.1 (75.1) 0.428 0.267 0.702
Mean corrected calcium, mg/l (SD) 80.2 (13.7) 79.6 (14.0) 80.9 (13.7) 82.0 (11.4) 80.9 (13.2) 77.6 (15.6) 0.411 0.523 0.829
Mean phosphate, mg/l (SD) 72.6 (35.2) 85.4 (55.2) 66.0 (30.1) 75.6 (28.0) 66.4 (31.1) 78.2 (33.7) 0.020 0.037 0.270
Planned dialysis start, n (%) 74 (11.2) 8 (6.7) 16 (10.5) 7 (6.3) 23 (14.8) 20 (16.5) 0.031 0.007 0.518
Median dialysis duration, days (Q1-Q3) 187 [37–754] 15 [6–298] 197 [44–836] 218 [57–855] 580 [119–977] 179 [62–357] <0.0001 0.630 0.173
Background nephropathy, n (%) 0.622 NA 0.328
Hypertension 187 (28.3) 35 (29.2) 40 (26.1) 37 (33.3) 40 (25.6) 35 (28.9)
Diabetes 92 (13.9) 16 (13.3) 19 (12.4) 18 (16.2) 21 (13.5) 18 (14.9)
Hypertension and diabetes 48 (7.3) 10 (8.3) 11 (12.4) 8 (7.2) 10 (6.4) 9 (7.4)
Chronic glomerulonephritis 116 (17.5) 13 (10.8 27 (17.6) 25 (22.5) 34 (21.8) 17 (14.0)
HIV 44 (6.7) 8 (6.7) 11 (7.2) 5 (4.5) 10 (6.4) 10 (8.3)
Others 62 (9.4) 9 (7.5) 18 (7.2) 8 (7.2) 16 (10.3) 11 (9.1)
Unknown 112 (16.9) 29 (21.2) 27 (17.6) 10 (9.0) 25 (16.0) 21 (17.4)
Median Charlson Score (Q1-Q3) 1 [1–2] 1 [1–2] 1 [1–2] 1 [1–1] 1 [1–1] 1 [1–2] 0.044 0.007 0.751
Death overall, n (%) 297 (44.9) 27 (22.5) 98 (64.0) 55 (49.5) 68 (43.6) 49 (40.5) <0.0001 0.508 0.212
Death at 12 month, n (%) 177 (26.8) 9 (7.5) 57 (37.2) 33 (29.7) 34 (21.8) 44 (36.4) <0.0001 0.004 0.138
Death by follow-up duration <0.0001 NA 0.475
< 120 days 101 (15.3) 8 (6.7) 32 (20.9) 20 (18.0) 20 (12.8) 21 (17.4)
120–365 76 (11.5) 1 (0.8) 25 (16.4) 13 (11.7) 14 (9.0) 23 (19.0)
> 365 120 (18.1) 18 (15.0) 41 (26.8) 22 (19.8) 34 (21.8) 5 (4.1)
NA not applicable, Q1–Q3, 25th–75th percentiles, SD standard deviation
1 p-value for year-by-year variation
2 p-trend, p-value for the linear trend in the changes across years













participants. The distribution of the background ne-
phropathy was similar across years (p = 0.622) and in a
non-differential way between men and women (p = 0.328
for gender*year interaction). The baseline biological pro-
file of patients is also shown in Table 1 indicating the
expected high serum urea and creatinine, low
hemoglobin and calcium levels, which with the excep-
tion of serum urea did not vary across years of study
overall (all p ≥ 0.240) and by gender (all p ≥ 0.649 for
gender*year interaction) and did not display a linear
trend (all p ≥ 0.133 for linearity). Serum urea varied sig-
nificantly across years (p = 0.009) and in a linear fashion
(p = 0.003 for linearity) from 2.28 g/l in 2002–2004 to
2.80 g/l in 2011–2012. The Median Charlson score was
generally around one point score, with suggestion how-
ever of significant variations across years (p = 0.044) in a
linear fashion (p = 0.007), but not in a differential way
among men and women (p = 0.751 for gender*year
interaction).
Dialysis start and follow-up
In all, the start of dialysis was planned in 74 (11.2 %)
participants. This proportion varied from 6.7 % in 2002–
2004 to 16.5 % in 2011–2012 (p = 0.031). The pattern
across years was linear (p = 0.007) with no evidence of
heterogeneity between men and women (p = 0.518 for
gender*year interaction). The median duration [25th-75th
percentiles] on dialysis was 187 [34–754] days overall
and varied from 15 [6–298] days in 2002–2004 to
179 [62–357] days in 2011–2012, with a pic of 580
[119–977] in 2009–2010. Variations across years were
statistically significant (p < 0.0001) but not in a linear
fashion (p = 0.630), nor in differential ways between
men and women (p = 0.173 for gender*year inter-
action), Table 1.
Mortality and determinants during follow-up
A total of 297 (44.9 %) deaths were recorded during
follow-up. This proportion rose from 22.5 % in 2002–
2004 to 64.0 % in 2005–2006 and steadily decreased
thereafter down to 40.5 % in 2011–2012 (p < 0.0001 for
year by year variation, and p = 0.508 for linear trend),
similarly in men and women (p = 0.212 for gender*year
interaction). The death rate at 12 months of follow-up
was 26.8 % (n = 177), with again similar variations across
years (p < 0.0001). Overall, 101 (34 %) deaths occurred
within 120 days of starting dialysis; 76 (25.6 %) within
120–365 days and 120 (40.4 %) beyond 365 days, Table 1.
The survival probability from the Kaplan-Meier estima-
tor for all-cause mortality is illustrated in Fig. 1.
In sex and age adjusted Weibull regression analyses,
year of study (p < 0.0001) and background nephropathy
(p = 0.0001) were significant predictors of mortality
while baseline Charlson score (p = 0.118) was borderline
(Table 2). In further multivariable models adjusted for
these factors, year of study and background nephropathy
(both p < 0.0001) remained the main predictors of
mortality during follow-up. Compared with the year
Fig. 1 Survival probability from Kaplan-Meir estimator showing the cumulative distribution function (solid curve) and the 95 % confidence interval
(dotted lines about) for mortality during follow-up of patients with end-stage renal disease (ESRD) who started dialysis at the Douala General
Hospital between 2002 and 2012. Broken horizontal and vertical lines have been added at regular intervals to assist interpretation
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2002–2004, all other years of study were associated with
higher risk of mortality with magnitude ranging from 73
to 229 % (Table 2). Using hypertension alone as a refer-
ent background nephropathy, diabetes alone was associ-
ated with 83 % (26–166 %) higher risk mortality while
diabetes combined with hypertension was associated
with 127 % (40–267 %) higher risk of mortality. Further-
more ESRD of unknown etiology was associated with
99 % (36–191 %) higher risk of mortality, while with ref-
erence to a Charlson score of 1 point, a score of 4 was
associated with 111 % (10–307 %) higher risk. The latter
however was based on small numbers as indicated by
the wide confidence intervals. The pattern was mostly
similar, but the magnitude of the association differed
(being much higher) when the logistic regression models
were applied to investigate the predictors of mortality
both for the entire duration of follow-up (Table 3) and
after restriction to the first 12 months of follow-up (Data
not shown). Furthermore, there was a linear trend in the
association of mortality risk with increasing Charlson
score (all p < 0.07 for linear trend).
Discussion
In this study based on a large sample of patients started
on renal replacement therapy for ESRD, we have for the
first time in Cameroon and to some extent in SSA, care-
fully characterised the mortality pattern and determinants
over time, using data from a referral dialysis centre. Death
rate among patients starting RRT in this setting is un-
acceptably high, with over a quarter of patients dying
within the first year of starting dialysis, and half of those
deaths occurring within the first six months. The baseline
background nephropathy appears to be a major determin-
ant of mortality, with the combination of diabetes and
hypertension conveying an excess risk. Our year-by-year
analyses further suggested an improvement over time in
Table 2 Age sex and year of study adjusted predictors of death from Weibull regression models
Variable Basic models Multivariable models
HR (95 % CI) P-value HR (95 % CI) P-value
Age, per year 0.99 (0.99–1.00) 0.412 0.99 (0.98–1.00) 0.517
Sex (men) 0.90 (0.71–1.15) 0.246 0.92 (0.72–1.18) 0.182
Year <0.0001 <0.0001
2002–2004 1 (reference) 1 (reference)
2005–2006 2.55 (1.62–3.99) 2.95 (1.85–4.67)
2007–2008 2.02 (1.24–3.27) 2.40 (1.44–3.98)
2009–2010 1.49 (0.93–2.39) 1.73 (1.06–2.82)
2011–2012 2.82 (1.70–4.67) 3.29 (1.94–5.58)
Background nephropathy 0.0001 <0.0001
Hypertension 1 (reference) 1 (reference)
Diabetes 1.80 (1.24–2.62) 1.83 (1.26–2.66)
Hypertension and diabetes 2.31 (1.44–3.72) 2.27 (1.40–3.67)
Chronic glomerulonephrities 1.08 (0.72–1.62) 1.08 (0.72–1.64)
HIV 1.63 (0.99–2.69) 1.17 (0.64–2.16)
Others 1.03 (0.66–1.61) 0.99 (0.63–1.56)
Unknown 1.97 (1.35–2.87) 1.99 (1.36–2.91)
Charlson score 0.118 0.124
1 1 (reference) 1 (reference)
2 1.09 (0.73–1.63) 1.02 (0.67–1.54)
3 1.23 (0.83–1.82) 1.39 (0.85–2.26)
4 2.07 (1.10–3.88) 2.11 (1.10–4.07)
Planned dialysis start 0.86 (0.60–1.23) 0.422 -
Haemoglobin, per g/dl 0.99 (0.92–1.06) 0.702 -
Serum creatinine, per 10 mg/l 1.00 (0.98–1.02) 0.884 -
Calcium, per 10 mg/l 0.96 (0.85–1.08) 0.532 -
Phosphate, per 10 mg/l 1.01 (0.96–1.07) 0.633 -
95 % CI, 95 % confidence interval, HR hazard ratio
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the proportion of patients starting RRT following a
planned program, but the overall proportion of patients in
the category remained unacceptably low.
Mortality in patients commencing or receiving dialysis
has been reported in few previous studies in SSA. In a
study of 40 incident dialysis cases in Ghana, 32 % of
patients died within 90 days of starting dialysis [18]. In a
similar study in 91 incident dialysis in Ethiopia, the
death rate was 23 % at 90 days, and only 42 % of patients
were still alive after 1 year [19]. In a series of 760 ESRD
patients managed over a 19-year period (including 565
via dialysis) at a referral hospital in the South-East of
Nigeria, 87 % of patients died within the first month of
treatment, and at 3 months only 6.8 % of patients receiv-
ing haemodialysis were still alive [11]. The 1-year mor-
tality rate was 7.4 % in a cohort of 242 prevalent
haemodialysis cases in Sudan [20]. Late presentation (or
referral) with CKD and affordability are often cited as
major drivers of the high early mortality among patients
starting chronic dialysis in SSA.
Differences in dialysis-related medical care influence
early dialysis mortality. Interventions identified as im-
portant include timely access to pre-ESRD nephrology
care, ESRD education and support services, treatment of
biochemical abnormalities in advanced CKD, and timely
placement of a permanent vascular access. The high
early dialysis mortality rate in our study is likely attribut-
able in part to poor quality of care prior to referral,
financial constraint, the lack of a national screening and
management programs for CKD, the limited number of
nephrologists in the country, the high number of late re-
ferral [21] and the lack of preparation for dialysis as well
Table 3 Age sex and year of study adjusted predictors of death from logistic regression models
Variable Basic models Multivariable models
OR (95 % CI) p-value OR (95 % CI) p-value
Age, per year 1.00 (0.99–1.01) 0.844 0.99 (0.97–1.01) 0.282
Sex (men) 0.90 (0.64–1.26) 0.530 0.86 (0.61–1.22) 0.400
Year <0.0001 <0.0001
2002–2004 1 (reference) 1 (reference)
2005–2006 6.14 (3.57–10.56) 7.25 (4.13–12.75)
2007–2008 3.38 (1.91–5.96) 3.86 (2.13–7.00)
2009–2010 2.64 (1.55–4.49) 2.91 (1.67–5.08)
2011–2012 2.33 (1.22–4.09) 2.72 (1.52–4.88)
P for linear trend 0.548 0.451
Background nephropathy 0.108 0.056
Hypertension 1 (reference) 1 (reference)
Diabetes 1.94 (1.14–3.30) 2.00 (1.17–3.43)
Hypertension and diabetes 2.00 (1.02–3.92) 1.99 (1.00–3.95)
Chronic glomerulonephrities 1.10 (0.63–1.92) 1.08 (0.61–1.92)
HIV 1.64 (0.81–3.32) 0.81 (0.31–2.14)
Others 1.19 (0.64–2.18) 1.03 (0.54–1.95)
Unknown 1.67 (1.00–2.80) 1.76 (1.04–2.99)
Charlson Score 0.071 0.045
1 1 (reference) 1 (reference)
2 1.15 (0.66–1.98) 1.12 (0.63–1.98)
3 1.58 (0.89–2.79) 2.13 (0.96–4.75)
4 4.03 (1.18–13.79) 5.15 (1.39–18.99)
P for linear trend 0.013 0.013
Planned dialysis start 1.27 (0.76–2.11) 0.355
Haemoglobin, per g/dl 1.00 (0.91–1.10) 0.950 -
Creatinine, per 10 mg/l 1.00 (0.98–1.02) 0.959 -
Calcium, per 10 mg/l 1.03 (0.87–1.22) 0.711 -
Phosphate, per 10 mg/l 1.01 (0.94–1.08) 0.804 -
95 % CI, 95 % confidence interval, OR odd ratio
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as exceptionally high number of unplanned start of dia-
lysis and twice weekly dialysis schedule could explain
this situation in our setting [22, 23]. Some other causes
of poor outcomes of patients on haemodialysis in
Cameroon may include low socioeconomic status of
haemodialysis patients, low social support, non-
adherence to diet and treatments. Since the year 2002,
dialysis is highly subsidized in public health facilities.
While, these subsidies cover nearly 95 % of cost of dialy-
sis session, patients and family still have to pay for the
costs of all concurrent treatments, laboratory investiga-
tions and incident hospitalisations; which for the major-
ity of patients, are unaffordable [13]. Studies elsewhere
have highlighted catheter use and late or absent pre-
ESRD nephrology care, as well as malnutrition as
captured by hypoalbuminemia, as major ‘reversible’
determinants of early dialysis mortality [24, 25].
Although some existing studies from Africa have col-
lected data across years, none has presented sufficiently
time-trend data for comparisons. The largest study is
from Arogundade et al. in Nigeria [11], and has covered
a 19-year’s period (1989–2007). In this study, the back-
ground nephropathy appeared to be similar across time
periods; in line with our findings of no significant vari-
ation in background nephropathies across years. We
however observed significant variations in mortality
rates across years, not explained by varying lengths of
exposure to dialysis, and other study characteristics. The
apparent low mortality rate in the first years of study
likely reflect incomplete follow-up. This is reflected by
the very short duration of follow-up on dialysis, implying
that patients were transferred to other centres soon after
the start of the dialysis, dropped out of dialysis, or per-
haps died in other settings. Between 2005 and 2010,
death rate mostly declined, likely reflecting the better
staffing of the service with initially one nephrologist,
then subsequently two. Further increase in mortality rate
in the last years of study are likely explained by severe
shortage of consumables for dialysis experienced by the
service and other centres across the country during
those 2 years. Over the years covered by the study, con-
ditions to access dialysis in public institutions have
mostly remained the same. However issues with the sup-
ply chain for dialysis consumable, which occurred in dif-
ferential ways across years, could be a major driver of
differences in mortality across years. We also noted that
an increasing proportion of patients started dialysis in
planned manners across years; however their absolute
number was very small to affect early mortality [26].
We found background nephropathy to be a determin-
ant of the overall and early mortality, with the combin-
ation of diabetes and hypertension conferring very high
risk, followed by diabetes alone, unknown aetiologies
and glomerulonephritis. In general, people with diabetes
tend to have many co-morbidities, are at high risk of fatal
infections on temporary vascular access, cardiovascular
and all-cause mortality. In general, the poor survival in dia-
lysis of patients with diabetes is well documented [27, 28].
Patients with ESRD of unknown aetiology are also more
likely to carry a high burden of co-morbidities, some of
which on their own (like undiagnosed cancers) are highly
fatal regardless of RRT. Across existing studies from Africa,
advanced uraemia, cardiovascular diseases and infections
have variably been reported as causes of death in patients
starting dialysis [11, 19, 22, 23].
Strengths and limitations
Our study has some limitations. Analyses are based on
data found in records, therefore precluding the investi-
gation of the broad spectrum of predictors of mortality
in dialysis, as well as the whereabouts of the defaulters.
Furthermore, we completely lacked data on causes of
death which were not assessed in this study. Data were
collected from a single centre, which could raise issues
regarding the generalizability to the entire country.
However, the study centre is the only public institution
to provide sufficient data for the range of time covered
in the current study. The background nephropathy in
these patients mostly reporting with advanced CKD was
essentially based on clinical arguments. Such an ap-
proach is not all accurate considering for instance that
the differentiation between hypertension causing ESRD
and hypertension resulting from or co-occurring with
ESRD may not be possible from a cross-sectional ana-
lysis. Our study also has major strengths including the
large sample size and the long period of data collection.
Our study is one of the largest to provide time-trend on
the outcomes of contemporary patients commencing
hemodialysis in SSA, and using robust analytic methods.
Conclusion
In conclusion, mortality in patients with ESRD commen-
cing dialysis in our setting is very high, with about 15 %
of patients dying within the first 120 days of starting
haemodialysis. In spite of some improvement over times,
the overall and early mortality rates have remained un-
acceptably high in these patients, and far above rates re-
ported in developed countries. Because most of these
premature deaths are potentially preventable, additional
efforts are needed in this setting to offset the risk and
maximise the benefits from the ongoing investments of
the government to defray the cost of haemodialysis.
Potential actions include intensive sensitisation of the
population and healthcare practitioners, in order to im-
prove early detection and referral of individuals with
CKD; and additional subsidies to support the cost of
managing co-morbidities in patients with CKD in
general.
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